<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817659</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 778967</org_study_id>
    <nct_id>NCT02817659</nct_id>
  </id_info>
  <brief_title>To Determine Tolerability to Glucagon Infusion in Obese Subjects</brief_title>
  <acronym>GIO</acronym>
  <official_title>A Pilot Study to Determine Tolerability to Glucagon Infusion in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To further understand the tolerability of glucagon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the tolerability of glucagon infusion administered in an escalating step-wise
      manner in healthy obese subjects
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure glucagon tolerance in healthy obese subject prior to subject becoming significantly nauseous.</measure>
    <time_frame>Visit 1, measured at 30 minutes</time_frame>
    <description>Glucagon infused in escalating manner. Each dose administered for 60 minutes. Intensity of nausea measured by administering a questionnaire that measures overall nausea intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure glucagon tolerance in healthy obese subject prior to subject becoming significantly nauseous.</measure>
    <time_frame>Visit 1, measured at 60 minutes</time_frame>
    <description>Glucagon infused in escalating manner. Each dose administered for 60 minutes. Intensity of nausea measured by administering a questionnaire that measures overall nausea intensity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Glucagon Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Glucagon infusion</description>
    <arm_group_label>Glucagon Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-55 years, inclusive

          2. BMI ≥27 to ≤40 kg/m2

          3. Stable body weight for 3 months (self-reported loss/gain &lt;5%)

          4. Subject is judged to be non-diabetic and in good health on the basis of medical
             history, physical examination, electrocardiogram, and routine laboratory data

          5. Subject understands the procedures and agrees to participate in the study program by
             giving written informed consent, and is willing to comply with the trial restrictions

          6. Subject is willing to avoid alcohol consumption for 48 hours prior to the inpatient
             study visit

          7. Subject is willing to avoid consumption of caffeine and caffeinated beverages for 24
             hours prior to the inpatient study visit

          8. Subject is willing to avoid strenuous physical activity for 72 hours prior to the
             inpatient study visit

          9. Female subjects of child bearing potential must be willing to use acceptable birth
             control during study participation (oral contraceptives, intrauterine device,
             implanted or injectable contraceptives, abstinence).

        Exclusion Criteria:

          1. Treatment with any medication known to significantly impact body weight (e.g., weight
             loss medications, atypical antipsychotics) within 3 months prior to screening except
             for stable physiological hormone replacement therapy (i.e., thyroid hormone, estrogen)

          2. History of bariatric surgery

          3. Current liver, renal, pulmonary, cardiac, oncologic, metabolic, gastrointestinal or
             hematologic disease which the Investigator believes is clinically significant,
             including:

               1. Liver disease or liver injury as indicated by abnormal liver function tests
                  (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase ,
                  serum bilirubin) &gt;3 × upper limit of normal (ULN), or history of hepatic
                  cirrhosis

               2. History or presence of impaired renal function as indicated by an estimated
                  glomerular filtration rate &lt;60 ml/hr or urine albumin-to-creatinine ratio &gt;35
                  mg/mmol

               3. Significant cardiovascular disease, including Class III or greater congestive
                  heart failure (CHF), coronary artery disease, second degree or greater heart
                  block, or clinically significant arrhythmias; baseline second degree or greater
                  heart block or prolonged QT syndrome (QTc interval ≥ 470 msec); or any major
                  cardiovascular event within the last 3 years (including myocardial infarction,
                  transient ischemic attack [TIA], cerebrovascular accident [CVA], angina, and
                  hospitalization due to CHF, transient ischemic attack (TIA), and CVA)

               4. Metabolic, other or endocrine disorders, including diagnosis of type 1 or type 2
                  diabetes mellitus [HbA1c ≥6.5%]), inadequately treated hyperthyroidism (thyroid
                  stimulating hormone [TSH] below normal range) or hypothyroidism (TSH above upper
                  limit of normal if symptomatic or TSH &gt;10 U/mL), Cushing syndrome, Addison's
                  disease, hypogonadism, or genetic disorders linked to obesity

               5. History of irritable bowel disease, recurrent nausea or vomiting

               6. Anemia (hemoglobin &lt;12 g/dl in men, &lt;11 g/dl in women)

          4. Self-reported history of hepatitis B, hepatitis C, or HIV

          5. History of recurrent sleep disturbances and/or prone to sleep disturbances based on
             lifestyle or employment (e.g., variable work schedule, overnight shift work, etc.)

          6. Diagnosis of sleep apnea with or without use of (continuous positive airway pressure)

          7. Major surgery within last 3 months

          8. Blood donation within 4 weeks prior to the screening visit

          9. Participation in another investigational trial within 4 weeks prior to the screening
             visit. The 4 week window will be derived from the date of the last trial medication
             and/or blood collection in a previous trial and/or adverse event (AE) related to trial
             drug to the screening visit of the current trial.

         10. Illicit drug abuse or use of nicotine-containing products within 3 months prior to the
             screening visit

         11. Poor intravenous access

         12. Blood pressure less than 100/50 mm Hg or greater than or equal to 160/100 mm Hg at
             screening visit

         13. Heart rate greater than or equal to 100 beats/min at screening visit

         14. Fasting plasma glucose &lt;60 mg/dL or ≥126 mg/dL at screening visit

         15. Translational Research Institute (TRI) staff member or immediate relative of TRI staff
             member, directly involved with this study

         16. History of any illness or condition that, in the opinion of the study investigator,
             might confound the results of the study or poses an additional risk to the subject by
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prinicipal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Florida Hospital Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum in: Lancet. 2010 Mar 20;375(9719):984.</citation>
    <PMID>19853906</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.</citation>
    <PMID>10757621</PMID>
  </reference>
  <reference>
    <citation>Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012 Mar;153(3):1039-48. doi: 10.1210/en.2011-1499. Epub 2011 Dec 13. Review.</citation>
    <PMID>22166985</PMID>
  </reference>
  <reference>
    <citation>SCHULMAN JL, CARLETON JL, WHITNEY G, WHITEHORN JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957 Nov;11(3):419-21.</citation>
    <PMID>13480952</PMID>
  </reference>
  <reference>
    <citation>Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987 May;64(5):896-901.</citation>
    <PMID>2881943</PMID>
  </reference>
  <reference>
    <citation>Calles-Escandón J. Insulin dissociates hepatic glucose cycling and glucagon-induced thermogenesis in man. Metabolism. 1994 Aug;43(8):1000-5.</citation>
    <PMID>8052138</PMID>
  </reference>
  <reference>
    <citation>Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, Buckley A, Win Z, Al-Nahhas A, Rabiner EA, Gunn RN, Budge H, Symonds ME, Bloom SR, Tan TM, Dhillo WS. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016 Jan;18(1):72-81. doi: 10.1111/dom.12585. Epub 2015 Nov 20.</citation>
    <PMID>26434748</PMID>
  </reference>
  <reference>
    <citation>Melzack R, Rosberger Z, Hollingsworth ML, Thirlwell M. New approaches to measuring nausea. CMAJ. 1985 Oct 15;133(8):755-8, 761.</citation>
    <PMID>4042058</PMID>
  </reference>
  <reference>
    <citation>Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KC, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013 Apr;62(4):1131-8. doi: 10.2337/db12-0797. Epub 2012 Dec 17.</citation>
    <PMID>23248172</PMID>
  </reference>
  <reference>
    <citation>Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR. Hormonal control of substrate cycling in humans. J Clin Invest. 1988 May;81(5):1545-55.</citation>
    <PMID>3284915</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

